Maxygen News

Maxygen, Inc. , a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced that it has extended the expiration date for its modified "Dutch Auction" tender offer to repurchase 6,557,377 shares of its common stock, which was commenced on November 13, 2009.

STOCK MARKETING INC PRESENTS : Encore Renaissance Resources Corp., Silicon Motion Technology Corp., Inc., WebMD Health Corp., PURE Bioscience, Maxygen, Inc., Qiao Xing Universal Telephone, Inc.

Biotechnology company Maxygen Inc. said Friday it extended its tender offer aimed at buying back just under 6.6 million shares of common stock.

Maxygen Inc. on Friday became the latest member of a very small biotech cadre that is returning cash to shareholders.

Shares of the following companies are having unusual moves in U.S. trading this morning.

All times in Eastern Time. REDWOOD CITY, Calif.-- --Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced financial results for the quarter end... SAN JOSE, Calif.-- --Brocade today announced that it expects to report financial results for its fourth quarter and fiscal year 2009 on Tuesday, ...

MTV is going ahead with plans to air the late DJ AM's "Gone too Far" documentary series, in which he and concerned families staged interventions for young drug abusers, with the first episode set to air Monday.

As a result of these... AUSTIN, Texas-- --LL&E Royalty Trust announced today that there will be no Trust income distribution for the month of October 2009 for Unit holders of record on October 5... NEW YORK-- --Fitch Ratings has withdrawn Popular Mortgage Servicing Inc.'s U.S. residential primary servicer rating as follows: -- Residential primary ...

Maxygen Inc. named a new CEO, extended a consulting agreement with a private investment firm led by its executive chairman and beefed up non-employee board members' compensation.

Maxygen Inc. said Monday its CEO and chief financial officer will leave the company on Wednesday, in keeping with a collaboration with Astellas Pharma Inc.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, announced that it will release its second quarter 2009 financial results on Thursday, August 6, 2009 at approximately 4:00 p.m. ET .

FDA Calendar Updates: Watson , Maxygen , BioMarin , OSI Pharma BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has new updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

G34 was Effective in Reducing Chemotherapy-Induced Neutropenia in this Study- -Based on Recent FDA Feedback, Maxygen Foresees a Timely and Cost Effective Path to BLA Submission- -Maxygen Continues Efforts to Out-License or Sell MAXY-G34 CIN Rights- REDWOOD CITY, Calif.-- --Jul 14, 2009 - Maxygen, Inc.

REDWOOD CITY, Calif.-- --Maxygen, Inc. today announced that Astellas Pharma Inc.

Biotechnology firm Maxygen Inc. has gotten a life- saving assist from Astellas Pharma Inc.

Maxygen, Inc. today announced that Astellas Pharma Inc. and Maxygen have executed an agreement to establish a joint venture focused on the discovery, research and development of multiple protein pharmaceutical programs, including Maxygen's MAXY-4 program and other early stage programs.